??i t??ng có nguy c? b? u lành tính nh? ph? n? sau 35 tu?i, ph? n? sau sinh ?? ho?c nh?ng ch? em b? r?i lo?n n?i ti?t t?.carriers can be superior candidates for therapy with one-agent PARP inhibitors than triple-unfavorable breast most cancers BRCA1In case of pT2 pN0 a taxane based polychemotherapy plus trastuzumab monotherapy is suggested which